Printer Friendly

Transgene receives patents covering homologous recombination technology in E. coli for fast generation of vectors.

Transgene (Strasbourg, France; 33-3-88-27-91-21), announced that it has been issued European Patent 742 834 and United States Patent 6,110,735 covering a method for the preparation of recombinant viral vectors by intermolecular homologous recombination. The technology enables the highly efficient and fast generation of new vectors, in particular adenoviral vectors, and has very broad potential applications.

Recombinant adenovirus vectors are a useful system for mammalian gene transfer, widely used in gene therapy, but also to study gene expression in vitro and in vivo. The potential applications for these vectors range from the study of gene functions to the production of high levels of recombinant proteins, recombinant vaccines and gene therapy. Generation of the recombinant adenoviral vectors is classically performed in eukaryotic cells, such as mammalian cells. However, these systems although they initially made vector generation possible, are strongly limited by their low efficiency.

The main feature of the method described in the patents consists of separately constructing the viral vector in bacterial systems and then producing the vector in the appropriate human complementation cell lines. Assembly of the complete viral genome occurs very rapidly in the prokaryotic host, thus allowing the entire process of virus generation and isolation to be completed within one month instead of several months by traditional methods.

Besides enabling Transgene to rapidly generate adenoviral vectors for its gene therapy programs, the technology has also already shown its usefulness in the field of functional genomics, for example in high throughput screening of gene functions.

"These new patents, combined with other intellectual properties covering both advanced defective adenoviral vectors and complementation cell lines, are yet again strengthening our leading position in the field of adenoviral vector technology," said Bernard Gilly, chief executive officer. "We will make the technology available for licenses to interested parties."

Transgene is a biopharmaceutical company dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired or inherited diseases for which there is no cure or adequate therapy at present. The company's proprietary technology platform consists of multiple vector families with a special emphasis on vaccinia virus, adenovirus, and synthetic vectors. Transgene has five products in clinical development to treat a variety of cancer indications, including two in phase II clinical trials and three in phase I clinical trials.
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Transgene receives patents covering homologous recombination technology in E. coli for fast generation of vectors.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Oct 1, 2000
Previous Article:GeNeuron announces issuance of United States patent.
Next Article:Vertex Pharmaceuticals receives United States patent covering assay technology to accelerate drug discovery targeting hepatitis C protease.

Related Articles
Transgene awarded European patent covering non-viral gene delivery technology.
Transkaryotic receives patent for gene targeting technology.
Athersys obtains United States patent.
Crucell obtains United States patent.
Lexicon Genetics broadens patent portfolio with knockout mouse patent.
Athersys obtains United States patent.
Plant Bioscience obtains United States patent.
DNA in GM food and feed.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters